Summary Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is
recommended for up to 1 year in patients with acute coronary syndrome receiving …

Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …

Abstract Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study
Comparing Two Forms of Anti-platelet Therapy After Stent Implantation) study randomly …

BACKGROUND: Dual antiplatelet therapy with aspirin and thienopyridines (clopidogrel or
prasugrel) is required after placement of coronary stents to prevent thrombotic …

Objectives The aim of this study was to evaluate the hypothesis that prasugrel monotherapy
following successful everolimus-eluting stent implantation is feasible and safe in patients …

Background: Limited data are available on short-term dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin …

Background: Optimal upfront dual antiplatelet therapy (DAPT) duration after complex
percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear …

Background—The risks and benefits of long-term dual antiplatelet therapy remain unclear.
Methods and Results—This prospective, multicenter, open-label, randomized comparison …

Background—The optimal duration of dual antiplatelet therapy (DAPT) after implantation of
drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month …

Background Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …